2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Klatskin Tumor
2
Cholangiocarcinoma
2
Sarcoma, Kaposi
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Liver Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Hepatocellular
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
447
Rituximab
406
Etoposide
225
Vincristine
217
Doxorubicin
204
Filgrastim
201
Prednisone
178
Cytarabine
160
Radiotherapy
152
fludarabine phosphate
148
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
130
Melphalan
128
fludarabine
116
Busulfan
101
Dexamethasone
93
Tacrolimus
76
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
72
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
63
Bendamustine Hydrochloride
63
Lenalidomide
62
Cyclosporine
62
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn